PL3449939T3 - Kompozycja farmaceutyczna do hamowania przerzutu nowotworowego zawierająca jako składnik czynny przeciwciało wiążące się swoiście z receptorem naskórkowego czynnika wzrostu - Google Patents

Kompozycja farmaceutyczna do hamowania przerzutu nowotworowego zawierająca jako składnik czynny przeciwciało wiążące się swoiście z receptorem naskórkowego czynnika wzrostu

Info

Publication number
PL3449939T3
PL3449939T3 PL16900546T PL16900546T PL3449939T3 PL 3449939 T3 PL3449939 T3 PL 3449939T3 PL 16900546 T PL16900546 T PL 16900546T PL 16900546 T PL16900546 T PL 16900546T PL 3449939 T3 PL3449939 T3 PL 3449939T3
Authority
PL
Poland
Prior art keywords
antibody
cancer
pharmaceutical composition
active ingredient
growth factor
Prior art date
Application number
PL16900546T
Other languages
English (en)
Inventor
Jong-Hwa Won
Yangmi LIM
Min-Kyu Hur
Original Assignee
Green Cross Corporation
Mogam Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corporation, Mogam Institute For Biomedical Research filed Critical Green Cross Corporation
Publication of PL3449939T3 publication Critical patent/PL3449939T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
PL16900546T 2016-04-27 2016-04-27 Kompozycja farmaceutyczna do hamowania przerzutu nowotworowego zawierająca jako składnik czynny przeciwciało wiążące się swoiście z receptorem naskórkowego czynnika wzrostu PL3449939T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/KR2016/004418 WO2017188472A1 (ko) 2016-04-27 2016-04-27 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암의 전이 억제용 약학 조성물
EP16900546.9A EP3449939B1 (en) 2016-04-27 2016-04-27 Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor

Publications (1)

Publication Number Publication Date
PL3449939T3 true PL3449939T3 (pl) 2022-06-20

Family

ID=60159801

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16900546T PL3449939T3 (pl) 2016-04-27 2016-04-27 Kompozycja farmaceutyczna do hamowania przerzutu nowotworowego zawierająca jako składnik czynny przeciwciało wiążące się swoiście z receptorem naskórkowego czynnika wzrostu

Country Status (13)

Country Link
US (1) US11198733B2 (pl)
EP (1) EP3449939B1 (pl)
JP (1) JP6701382B2 (pl)
KR (1) KR102128556B1 (pl)
CN (1) CN109195627B (pl)
DK (1) DK3449939T3 (pl)
ES (1) ES2912903T3 (pl)
HR (1) HRP20220576T1 (pl)
HU (1) HUE058745T2 (pl)
LT (1) LT3449939T (pl)
PL (1) PL3449939T3 (pl)
SI (1) SI3449939T1 (pl)
WO (1) WO2017188472A1 (pl)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790164B2 (en) 2006-11-14 2010-09-07 Van Andel Research Institute Fragments of antibodies to epidermal growth factor receptor and methods of their use
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
MX2012012441A (es) * 2010-05-04 2013-02-26 Merrimack Pharmaceuticals Inc Anticuerpos contra el receptor del factor de crecimiento epidermico (egfr) y usos de los mismos.
KR20130083090A (ko) 2012-01-10 2013-07-22 강원대학교산학협력단 암 세포의 ｅｇｆｒ에 특이적으로 결합하는 항체 및 이의 용도
EP3296320A1 (en) 2012-03-08 2018-03-21 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2872018A1 (en) 2012-05-17 2013-11-21 Sorrento Therapeutics, Inc. Antigen binding proteins that bind egfr
CA2915127A1 (en) 2012-06-06 2013-12-12 Giancarlo PARENTI Allosteric chaperones and uses thereof
WO2014173886A1 (en) * 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation

Also Published As

Publication number Publication date
JP2019514909A (ja) 2019-06-06
WO2017188472A1 (ko) 2017-11-02
HRP20220576T1 (hr) 2022-06-10
LT3449939T (lt) 2022-05-25
CN109195627B (zh) 2022-09-09
JP6701382B2 (ja) 2020-05-27
EP3449939B1 (en) 2022-03-30
KR20180137502A (ko) 2018-12-27
CN109195627A (zh) 2019-01-11
EP3449939A4 (en) 2019-12-18
KR102128556B1 (ko) 2020-06-30
SI3449939T1 (sl) 2022-06-30
US11198733B2 (en) 2021-12-14
ES2912903T3 (es) 2022-05-30
EP3449939A1 (en) 2019-03-06
HUE058745T2 (hu) 2022-09-28
US20190119388A1 (en) 2019-04-25
DK3449939T3 (da) 2022-05-02

Similar Documents

Publication Publication Date Title
HK1257646A1 (zh) 包含雙特異性抗體建構物之醫藥組合物
IL247722A0 (en) Pharmaceutical preparations containing active medicinal compounds for the treatment of hematological cancers
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
IL244206A0 (en) A pharmaceutical preparation containing a pyrimidine compound as an active ingredient
IL247721A0 (en) Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors
EP3081222A4 (en) Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
AU2016297823B2 (en) Methods for better delivery of active agents to tumors
HK1257615A1 (zh) 用於治療癌症、含有多酚化合物作為活性成分的藥物組合物
HK1250937A1 (zh) 穩定的包含cd147單克隆抗體的藥物製劑
IL272168A (en) The compositions for increasing the bioavailability of drugs, additives and substances for ingestion
ZA201805600B (en) Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof
EP3037092A4 (en) Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer or metastasis
LT3390450T (lt) Antii-cd28 humanizuoti antikūnai, paruošti vartoti žmonėms
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IL228019A (en) Compounds of histamine 3h receptor antagonists, a process for their preparation and uses
EP2697238A4 (en) SOLID FORMS OF ANTIRETROVIRUS COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION
HK1255877A1 (zh) 含有抗人tslp受體抗體的藥物組合物
HK1250935A1 (zh) 穩定的包含cd147單克隆抗體的藥物製劑
EP2910246A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE
EP3229025A4 (en) Method for assessing therapeutic effect of anti-cancer agent having anti-cd4 antibody as active ingredient
IL236437A (en) Acrylamide compounds as histamine h3 receptor ligands, process for preparation, medicinal preparations containing them and their uses
EP3323411A4 (en) Composition for inhibiting angiogenesis containing nanoparticle-vitreous body-based protein complex as active ingredient, and use thereof
HUE058745T2 (hu) Hatóanyagként epidermális növekedési faktor receptorhoz specifikusan kötõdõ antitestet tartalmazó gyógyászati készítmény rák áttételének gátlására
EP3053601A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER CONTAINING THE CYB5R3 GENE OR PROTEIN AS AN ACTIVE SUBSTANCE
EP3693388A4 (en) MONOCLONAL ANTIBODY FOR IL-5R